Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
It’s the law: Obama signs widely popular 21st Century Cures Act
9 years ago
GSK preps for vaccine R&D expansion, 200 hires for new global hub
9 years ago
R&D
Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead
9 years ago
R&D
Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca
9 years ago
R&D
The 21st Century Cures Act is here to stay. Now what?
9 years ago
Gilead offers rare apology to payers over the hep C drug sticker shock
9 years ago
Seasteader, drug libertarian and now FDA Commissioner? Peter Thiel backs a radical shift
9 years ago
PEOTUS Donald Trump vows to rein in drug prices, slamming biotech stocks
9 years ago
Is the US biopharma industry headed for a turning point in 2017?
9 years ago
Bioregnum
Opinion
Sarepta critic Jenkins is exiting the FDA, and Woodcock takes direct charge of the OND after a painful rupture
9 years ago
Rattled by immune responses, Spark will pay $30M-plus to get Selecta’s help in ending threat
9 years ago
R&D
Booming CRISPR pioneer Intellia looks to double staff with new digs
9 years ago
R&D
Round 2 in Boehringer's US reorganization will claim another 244 jobs, including small molecule group
9 years ago
R&D
Merck pulls the trigger on a new West Coast R&D campus in the heart of a mega-hub
9 years ago
Star-crossed AstraZeneca strikes a drug discovery deal with upstart Bicycle
9 years ago
21st Century Cures Act supporters crush meager House opposition, head to a final showdown in the Senate
9 years ago
In Lechleiter's final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion
9 years ago
R&D
Stubborn Actelion CEO Clozel spurs shift in buyout talks, but J&J counters with a raised bid -- reports
9 years ago
People
House lines up biotech lollipops as support grows for an epic 21st Century Cures Act
9 years ago
Will J&J come up with a big enough treasure trove to win an Actelion buyout?
9 years ago
Deals
R&D
Novartis swoops in to bag Selexys and its sickle cell drug in $665M deal
9 years ago
Dinner and a biotech chat: Billionaire Patrick Soon-Shiong talks 'innovation' with President-elect Trump
9 years ago
Donald Trump is starting to win over biopharma
9 years ago
People
Florida's decade-old incentive program to lure research institutions is going belly up
9 years ago
First page
Previous page
339
340
341
342
343
344
345
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit